Natasha Hunter

Featured in: Favicon

jamanetwork.com Favicon

cancernetwork.com Favicon

onclive.com Favicon

patientpower.info

Articles

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Aug 4, 2024 | cancernetwork.com | Sara A. Hurvitz |Anne F. Schott |Cynthia X. MA |Rita Nanda |George Zahrah |Natasha Hunter | +10 more

BackgroundVepdegestrant (ARV-471) is an oral proteolysis-targeting chimeric (PROTAC) estrogen receptor (ER) degrader with activity toward wild-type and mutant ER. The phase 2 expansion (VERITAC) of a phase 1/2 study tested 2 vepdegestrant doses (200 mg once daily and 500 mg once daily) in heavily pretreated patients with ER+/HER2-negative (HER2–) advanced breast cancer.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →